Version May 2024
Bacterial conjunctivitis: Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days, then instill 1 to 2 drops 4 times daily for an additional 5 days.
Corneal ulcer: Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 30 minutes while awake and every 4 to 6 hours at night for the first 2 days; beginning on day 3, instill 1 to 2 drops every hour while awake for 4 to 6 additional days; thereafter, 1 to 2 drops 4 times daily until clinical cure.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
(For additional information see "Ofloxacin (ophthalmic): Pediatric drug information")
Bacterial conjunctivitis: Children and Adolescents: Ophthalmic: Initial: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days (Days 1 and 2); then instill 1 to 2 drops 4 times daily for an additional 5 days (Days 3 through 7)
Corneal ulcer: Children and Adolescents: Ophthalmic: Initial: Instill 1 to 2 drops in affected eye(s) every 30 minutes while awake and every 4 to 6 hours at night for the first 2 days (Days 1 and 2); then instill 1 to 2 drops every hour while awake for 4 to 6 additional days (Days 3 through 7 to 9); thereafter, 1 to 2 drops 4 times daily until clinical cure is achieved
Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment is unlikely due to low systemic absorption.
Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment is unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined:
Central nervous system: Dizziness, foreign body sensation of eye
Gastrointestinal: Nausea
Ophthalmic: Blurred vision, burning sensation of eyes, conjunctivitis (chemical), eye discomfort, eye pain, eye pruritus, eye redness, keratitis (chemical), lacrimation, photophobia, stinging of eyes, swelling of eye, xerophthalmia
<1%, postmarketing, and/or case reports: Stevens-Johnson syndrome, toxic epidermal necrolysis
Hypersensitivity to ofloxacin, other quinolones, or any component of the formulation
Concerns related to adverse effects:
• Hypersensitivity reactions: Rare severe hypersensitivity reactions (some fatal), including anaphylaxis and anaphylactic shock, have occurred with systemic quinolone therapy (some following the first dose). Some reactions were accompanied by airway obstruction, angioedema (laryngeal, pharyngeal, or facial edema), cardiovascular collapse, dyspnea, loss of consciousness, pruritus, and urticaria. Discontinue treatment if an allergic reaction occurs.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection is suspected, institute appropriate alternative therapy.
• Tendon inflammation/rupture: There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following ophthalmic administration is substantially lower than with systemic therapy. Discontinue at first sign of tendon inflammation or pain.
Dosage form specific issues:
• Appropriate use: Not for subconjunctival injection or for introduction into the ocular anterior chamber.
Special populations:
• Contact lens wearers: Contact lenses should not be worn during treatment of ophthalmic infections.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Ocuflox: 0.3% (5 mL) [contains benzalkonium chloride]
Generic: 0.3% (5 mL, 10 mL)
Yes
Solution (Ocuflox Ophthalmic)
0.3% (per mL): $29.77
Solution (Ofloxacin Ophthalmic)
0.3% (per mL): $1.38 - $14.07
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Ocuflox: 0.3% (5 mL) [contains benzalkonium chloride]
For ophthalmic use only; not for subconjunctival or direct injection into the anterior chamber of the eye. Avoid touching tip of applicator to eye, fingers, or other surfaces.
For ophthalmic use only; not for subconjunctival or direct injection into the anterior chamber of the eye. To avoid excessive systemic absorption, apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration (Ref). Avoid touching tip of applicator to eye, fingers, or other surfaces.
Bacterial conjunctivitis: Treatment of bacterial conjunctivitis caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, and Pseudomonas aeruginosa.
Corneal ulcer: Treatment of corneal ulcers caused by S.aureus, S.epidermidis, S.pneumoniae, P.aeruginosa, Serratia marcescens, and Cutibacterium acnes.
Ocuflox may be confused with Occlusal-HP, Ocufen
None known.
There are no known significant interactions.
Adverse events have been observed in some animal reproduction studies. When administered orally, ofloxacin crosses the placenta (Giamarellou 1989). The amount of ofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).
When administered orally, ofloxacin enters breast milk. It is not known if ofloxacin is excreted into breast milk following ophthalmic application. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.
Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal
Absorption: Only small amounts are absorbed systemically after ophthalmic instillation.
Excretion: Urine
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
